Antiviral and Antifungal Review Flashcards
- 5’ monophosphate formed by a CMV viral kinase
- guanosine analog
- triphosphate formed by cellular kinases
- preferentially inhibits DNA polymerase
ganciclovir
- guanosine analogs, monophosphorylated by HSV/VZV thymidine kinase and not in uninfected cells –> few adverse effects
- preferentially inhibit DNA polymerase by chain termination
acyclovir, valacyclovir, famciclovir
- preferentially inhibits viral DNA polymerase, does not require phosphorylation by viral kinase
- treats CMV retinitis in immunocompromised patients, acyclovir resistant HSV, long half life
- nephrotoxicity
cidofovir
- viral DNA/RNA polymerase inhibitor and HIV reverse transcriptase inhibitor
- binds to pyrophosphate binding site of enzyme
- treats CMV retinitis when ganciclovir fails, acyclovir resistant HSV
- nephrotoxic, electrolyte abnormalities, seizures
foscarnet
-for primary keratoconjunctivitis and recurrent epithelial keratitis caused by herpes simplex I and II
trifluridine
for herpes simplex of face or lips, OTC
docosanol
- thymidine analog, substrate/inhibitor for HIV reverse transcriptase
- inhibits stable infection of new cells
- well absorbed, CNS, rapidly metabolized
- use in 3 or 4 drug cocktail for HIV, resistant due to mutations in reverse transcriptase
- adverse: bone marrow depression, CNS, toxicity in drugs competing for glucoronidation
zidovudine
zidovudine zalcitabine lamivudine abacavir tenofovir (nucleotide) emtricitabine
nucleoside reverse transcriptase inhibitors
- first gen oral NNRTI
- non competitive, binds near but not in active site
- rapid resistance
- can be active against AZT resistant HIV
- life threatening skin rash
- CPY3A4 substrate
non-nucleoside reverse transcriptase inhibitors (NNRTI)
nevirapine efavirenz delavirdine etravirine rilpivirine
NNRTIs
- prevent viral particle production, prevent maturation of new viruses, pol gene cleaves polypeptide products of mRNA
- adverse: hyperglycemia, altered fat distribution, hyperlipidemia, insulin resistance
HIV protease inhibitors
- first HIV protease inhibitor
- well tolerated
- low oral bioavailability
- extensive 1st pass
- DDIs
- use in combo with RT inhibitors
saquinavir
coformulated with protease inhibitors to “boost” levels, inhibitor of CYP3A4
ritonavir
- CCR5 antagonist
- binds CCR5 on human CD4 cells
- inhibits gp120 conformational change required for HIV fusion with CD4 cell
maraviroc
interferes with entry of HIV-1 into host cells by inhibiting the fusion of virus and cell membranes, binds gp41
enfuvirtide
-inhibit catalytic activity of integrase
dolutegravir, elvitegravir, raltegravir
- antimetabolite, blocks GMP formation
- aerosol for RSV
- known teratogen, dose dependent myelosuppression
- treatment of hepatitis
ribavirin
- oral agent effective against all common influenza viruses
- pro drug
- NA inhibitor
oseltamivir
- oral inhalation
- influenza A and B
- effective in early infection
- bronchospasm in asthmatics
zanamivir
- treatment of acute, uncomplicated influenza in adults who’ve been symptomatic <2 days
- 600 mg single dose
peramivir
- block viral uncoating by blocking M2 proton channel
- given in first 48 hours of contact
- admin orally, protects only influenza A
amantadine, rimantadine
standard of care for treatment of HCV?
peginterferon alfa + ribavirin